MIVI Neuroscience announced that the FDA has approved an investigational device exemption to initiate a human clinical study of the MIVI Q aspiration catheter in the United States. EVaQ is a prospective, multicenter, single-arm study of the Q revascularization system for neurointervention in acute ischemic stroke. According to the company, the study will assess the
SNIS has developed a set of care recommendations for neurointerventional physicians that cover management of stroke thrombectomy with an emphasis on safety measures for health care providers. The recommendations include guidance for treating patients who are COVID-positive, COVID-negative, or COVID-undocumented. As the COVID-19 pandemic continues to unfold, SNIS will consider revisiting their recommendations if needed
MicroVention, Inc., a U.S. based subsidiary of Terumo and a global neurovascular company announced the FDA Premarket Approval (PMA) for the FRED® (Flow Re-Direction Endoluminal Device) device for the treatment of brain aneurysms. The FRED® device is the first flow diverter in the U.S. to use a self-expanding braided nitinol mesh to help re-direct blood
